Find information on thousands of medical conditions and prescription drugs.

Danazol

Danazol is a derivative of the synthetic steroid ethisterone, a modified testosterone. It was approved by the FDA as the first drug to treat specifically endometriosis, but its role as a treatment for endometriosis has been largely replaced by the GnRH agonists. more...

Home
Diseases
Medicines
A
B
C
D
Dacarbazine
Dactinomycin
Dalmane
Danazol
Dantrolene
Dapoxetine
Dapsone
Daptomycin
Daraprim
Darvocet
Darvon
Daunorubicin
Daunorubicin
Daypro
DDAVP
Deca-Durabolin
Deferoxamine
Delsym
Demeclocycline
Demeclocycline
Demerol
Demulen
Denatonium
Depakene
Depakote
Depo-Provera
Desferal
Desflurane
Desipramine
Desmopressin
Desogen
Desogestrel
Desonide
Desoxyn
Desyrel
Detrol
Dexacort
Dexamethasone
Dexamfetamine
Dexedrine
Dexpanthenol
Dextran
Dextromethorphan
Dextromoramide
Dextropropoxyphene
Dextrorphan
Diabeta
Diacerein
Diacetolol
Dial
Diamox
Diazepam
Diazoxide
Dibenzepin
Diclofenac
Diclohexal
Didanosine
Dieldrin
Diethylcarbamazine
Diethylstilbestrol
Diethyltoluamide
Differin
Diflucan
Diflunisal
Digitoxin
Digoxin
Dihydrocodeine
Dihydroergotamine
Dihydrotachysterol
Dilantin
Dilaudid
Diltahexal
Diltiazem
Dimenhydrinate
Dimercaprol
Dimetapp
Dimethyl sulfoxide
Dimethyltryptamine
Dimetridazole
Diminazene
Diovan
Dioxybenzone
Diphenhydramine
Diphenoxylate
Dipipanone
Dipivefrine
Diprivan
Diprolene
Diproteverine
Dipyridamole
Disulfiram
Disulfiram
Dizocilpine
Dobutamine
Docetaxel
Docusate sodium
Dofetilide
Dolasetron
Dolobid
Dolophine
Domperidone
Donepezil
Dopamine
Dopram
Doral
Doramectin
Doriden
Dornase alfa
Doryx
Dostinex
Doxapram
Doxazosin
Doxepin
Doxil
Doxil
Doxorubicin
Doxy
Doxycycline
Doxyhexal
Doxylamine
Drisdol
Drixoral
Dronabinol
Droperidol
Drospirenone
Duloxetine
Durabolin
Duragesic
Duraphyl
Duraquin
Dutasteride
Dv
Dyclonine
E
F
G
H
I
J
K
L
M
N
O
P
Q
R
S
T
U
V
W
X
Y
Z

The agent is fat-soluble, has a molecular weight of 337.5. Its CAS registry number is 17230-88-5.

Danazol decreases the pituitary hormones FSH and LH and exerts an antiproliferative effect upon the endometrium, leading to amenorrhea. This effect is useful for patients with endometriosis. Commonly, pelvic pain associated with endometriosis is improved as well.

Androgenic side effects are of concern as in sensitive female individuals, Danazol can enhance unwanted heir growth leading to hirsutism. On rare occasion, it may deepen the voice. Other side effects could be acne and oily skin. As Danazol is metabolized by the liver, it cannot be used by patients with liver disease, and long-term use needs to monitor liver function on a periodic basis. Some patients who use Danazol may experience weight gain and fluid retention.

Contrary to GNRH agonists Danazol does not induce osteoporosis. Also, symptoms of hot flashes tend to be less common or severe.

Danazol is contraindicated in pregnancy as it could masculinize a female fetus.

Danazol has been used for other indications, namely in the management of menorrhagia, of fibrocystic breast disease, and of hereditary angioedema.

In the USA, Danazol was initially marketed as Danocrine, before it became available as a generic drug.

Read more at Wikipedia.org


[List your site here Free!]


A 25-year-old patient with spontaneous hemothorax
From CHEST, 10/1/05 by Hugh Black

A 25-year-old African-American woman with a chief complaint of progressive dyspnea and cough presented to the inpatient service after her primary care physician noted a significant right-sided pleural effusion on a chest radiograph. She had a 2-to 3-year history of intermittent, sharp, pleuritic chest pain radiating from the right subscapular region, across the anterior chest, and down the right arm that worsened with cough and accompanied this episode. Three months prior to hospital admission, dyspnea had developed with exertion and cough productive of white sputum. She sought medical attention 2 months prior to hospital admission, but two courses of outpatient antibiotic therapy did not ameliorate her condition. Her activity level deteriorated from unrestricted walking to dyspnea at rest.

She was receiving no medications, and did not drink alcohol, smoke cigarettes, or use recreational drugs. Coccidioidomycosis was previously diagnosed in a family member. The patient had noted occasional abdominal bloating, night sweats, and chills without fever, and an 8-lb unintentional weight loss over the previous 3 months. She had no known tuberculosis exposures, and a recent tuberculin skin test result was negative. She denied rash, joint pain, nausea, hemoptysis, orthopnea, hematochezia, dizziness, visual changes, dyspareunia, or dyschezia. She has a history of dysmenorrhea and was on her menses at the time of hospital admission.

In the emergency department, she was noted to have a large, right-sided pleural effusion (Fig 1). Thoracentesis revealed bloody fluid. A chest tube was inserted and drained 2.6 L of bloody pleural fluid.

[FIGURE 1 OMITTED]

On examination, the patient was a thin, African-American woman in no distress. Her chest examination revealed an appropriately placed chest tube, a soft-tissue fullness over her right scapula, which was tender to palpation, and absent breath sounds on the right side. Ascites, without organomegaly, was present on abdominal examination. The remainder of the examination was normal.

Admission chemistries, blood count, and coagulation panel were normal. Pleural fluid had a bloody appearance, with a lactate dehydrogenase level of 825 U/L and a protein level of 3.8 g/dL. Ascites fluid also had a bloody appearance, with 1.2 million RBCs/[micro]L. Further analysis of the pleural fluid later proved to be negative for acid-fast bacilli by smear, adenosine deaminase, and polymerase chain reaction analysis. Cytology of the pleural fluid was normal. ACT scan of the chest revealed a large, right-sided pleural effusion with extension into the left chest, and a localized area of pleural thickening (Fig 2). Pelvic CT scan showed a fullness between the anterior wall of the rectum and the uterus (Fig 3), and a transvaginal ultrasound revealed a mass in the uterine cul-de-sac. The patient was taken to the operating room for thoracotomy. No subscapular mass was noted, but several 1- to 3-cm brown nodules were noted on the surface of the right lower lobe. Wedge resection of the right lower lobe and pleural biopsies were performed. Pathology showed extensive organizing pleuritis without malignancy. Smears and culture for acid-fast bacilli were negative.

[FIGURES 2-3 OMITTED]

What is the diagnosis?

Diagnosis: Thoracic endometriosis syndrome with catamenial hemothorax

The differential diagnosis of bloody pleural effusions is relatively narrow. Trauma, iatrogenic or otherwise, represents the most common cause of hemothorax. Other common causes of bloody pleural effusion include malignancy (primary or metastatic), tuberculosis, pulmonary embolism, and serositis from collagen vascular diseases such as rheumatoid arthritis and systemic lupus erythematosus. Less common causes include pancreatitis and pseudocyst, leaking thoracic aneurysm, Meig syndrome from pelvic malignancy, and thoracic endometriosis syndrome with catamenial hemothorax.

Clinical Features

Since its identification as a clinical entity in 1953, (1) the thoracic endometriosis syndrome has remained a fleeting diagnosis. Diagnosis is often delayed for months or even years, a testament to the high index of suspicion the clinician must hold for its wide range of clinical presentations. Symptoms, signs, and pathologic states that recur in the chest with menses remain a hallmark of the disease. Such phenomena, termed catamenial by Dr. Lilington in 1972 (from the Greek: [kappa][alpha][tau][alpha] for concerning, and [mu][eta][upsilon] for month) (2,3) may take on a number of clinical manifestations, including pneumothorax, hemothorax, hemoptysis, pulmonary nodules, chest pain, dyspnea, and others. (4)

Catamenial hemothorax represents the second most common manifestation of thoracic endometriosis syndrome, occurring in 14% of known cases, and affects the right side > 80% of the time. Concomitant pelvic endometriosis was found in 100% of cases. (5) The majority of these patients were young, nulliparous, black women. (6) Intraoperative findings are reported to include chocolate-brown and bloody fluid, dense adhesions with a dense nodular peel, chocolate- and blue-colored nodules, and orange-red plaque-like lesions. (7-9) Importantly, only 71% of reported cases taken to surgery resulted in diagnostic pathology. One study (10) reported that pathologic identification of one case of thoracic endometriosis syndrome was only possible after a second set of samples from the original block was inspected. Thoracic endometrial tissue also undergoes cyclic expansion and recession concomitant with the menstrual cycle, (11,12) and this has been postulated as a reason for the discrepancy between pathologic data and clinical diagnosis. (4)

TREATMENT

The goal of medical therapy for the thoracic endometriosis syndrome is to minimize estrogen secretion. A number of hormonal agents, which mimic anovulation, pregnancy, or menopause, are utilized to achieve this objective. Danazol, a derivative of 17-[alpha]-ethinyltestostyerone, minimizes the midcycle surge of leutinizing hormone, thus mimicking the chronic anovulatory state. Progestational agents have been given to induce atrophy of endometrial tissue. Gonadotropin-releasing hormone agonists minimize follicle-stimulating hormone and leutinizing hormone secretion, inducing hypogonadotropic gonadism. Oral contraceptive pills, which cause amenorrhea, have also been used. (13)

In general, medical therapy alone is insufficient for the treatment of pleural manifestations of thoracic endometriosis. (4) Recurrence often necessitates pleural inspection, with resection of endometrial implants. Repair of diaphragmatic fenestrations has also been suggested. (14) Hysterectomy and oopherectomy have also been performed as a surrogate for hormonal therapy, with varied results. (4,5)

In our case, further questioning determined our patient had worsening chest pain and tenderness during menses. Furthermore, her chest tube output precipitously dropped from 200 to 300 mL of bloody fluid per day to close to zero coincident with the cessation of menses. In addition, thoracotomy was performed several days after her menses, which makes it less likely that we would have been able to identify active endometrial tissue from our biopsy samples. We presume the implants found at thoracotomy and the organizing pleuritis identified by pathology represents the residua of endometrial tissue that has receded since the end of menses. Based on these clinical features, we ascribed a clinical diagnosis of catamenial hemothorax with thoracic and peritoneal endometriosis to our patient. She was initially placed on danazol with plans to ultimately treat her with oral contraceptive pills. At 1- and 2-month follow-ups, her pleural disease had abated and her ascites had markedly improved.

Manuscript received December 1, 2004; revision accepted January 27, 2005.

REFERENCES

(1) Barnes J. Endometriosis of the pleura and ovaries. J Obstet Gynaecol Br Emp 1953; 60:823-824

(2) Lillington GA, Mitchell SP, Wood GA. Catamenial pneumothorax. JAMA 1972; 219:1328-1332

(3) Lidell H. Greek-English lexicon. 7th ed. Oxford, UK: Oxford University Press, 1990

(4) Johnson MM. Catamenial pneumothorax and other thoracic manifestations of endometriosis. Clin Chest Med 2004; 25: 311-319

(5) Joseph J, Sahn SA. Thoracic endometriosis syndrome: new observations from an analysis of 110 cases. Am J Med 1996; 100:164-170

(6) Bhojawala J, Heller DS, Cracchiolo B, et al. Endometriosis presenting as bloody pleural effusion and ascites-report of a case and review of the literature. Arch Gynecol Obstet 2000; 264:39-41

(7) Bhatia DS, McFadden PM, Kline RC. Recurrent catamenial hemopneumothorax. South Med J 1998; 91:398-401

(8) Moffatt SD, Mitchell JD. Massive pleural endometriosis. Eur J Cardiothorac Surg 2002; 22:321-323

(9) Shepard MK, Mancini MC, Campbell GD Jr, et al. Right-sided hemothorax and recurrent abdominal pain in a 34-year-old woman. Chest 1993; 103:1239-1240

(10) Flieder DB, Moran CA, Travis WD, et al. Pleuro-pulmonary endometriosis and pulmonary ectopic deciduosis: a clinicopathologic and immunohistochemical study of 10 cases with emphasis on diagnostic pitfalls. Hum Pathol 1998; 29:1495-1503

(11) Cassina PC, Hauser M, Kael G, et al. Catamenial hemoptysis: diagnosis with MRI. Chest 1997; 111:1447-1450

(12) Wang HC, Kuo PH, Kuo SH, et al. Catamenial hemoptysis from tracheobronchial endometriosis: reappraisal of diagnostic value of bronchoscopy and bronchial brush cytology. Chest 2000; 118:1205-1208

(13) Olive DL, Pritts EA. Treatment of endometriosis. N Engl J Med 2001; 345:266-275

(14) Bagan P, Le Pimpec Barthes F, Assouad J, et al. Catamenial pneumothorax: retrospective study of surgical treatment. Ann Thorac Surg 2003; 75:378-381

Hugh Black, MD; Darren Sigal, MD; David Barnes, MD; Chance Felisky, MD; Dave Follette, MD; and Richart Harper, MD, FCCP

* From the Division of Pulmonary and Critical Care Medicine (Drs. Black and Harper), Department of Internal Medicine (Dr. Sigal), Department of Emergency Medicine (Dr. Barnes), and Department of Cardiothoracic Surgery (Drs. Felisky and Follette), University of California at Davis School of Medicine, Davis, CA.

Correspondence to: Hugh Black, MD, Department of Internal Medicine, Division of Pulmonary and Critical Care Medicine, University of California at Davis School of Medicine, 4150 V St, Suite 3400, Sacramento, CA 95817; e-mail: hblack60@msn.com

COPYRIGHT 2005 American College of Chest Physicians
COPYRIGHT 2005 Gale Group

Return to Danazol
Home Contact Resources Exchange Links ebay